CDMO Capacity Pharma Manufacturing Examples
Decision brief
Answer first · skim in under a minute
This article examines the AI citation gap in CDMO capacity for pharmaceutical manufacturing, providing concrete examples and strategic insights. It clarifies the CDMO industry, compares CDMO vs CRO, and highlights top CDMO pharma companies.
CDMO capacity pharmaceutical manufacturing examples matter because sponsors rarely own every reactor, fill line, and release-testing suite they need. This analysis maps how FDA quality-agreement rules, drug-amount reporting, continuous manufacturing, and the Novo–Catalent fill-finish transfer define real capacity—not marketing claims.
Contents10 sections
Key Takeaways
- FDA’s contract-manufacturing quality-agreement guidance makes owners and contract facilities jointly responsible for documenting CGMP activities that underpin usable CDMO capacity.
- Novo Holdings closed the Catalent acquisition at about $16.5 billion enterprise value in December 2024; Novo Nordisk paid $11.7 billion for three fill-finish sites in Italy, Indiana, and Belgium.
- Continuous manufacturing is FDA’s leading advanced-manufacturing example for flexible output, yet adoption remains limited versus batch capacity still booked at CDMOs.
- Public filings and FDA pages still under-specify bioreactor liters and open vial slots, which is why AI answer engines often cite incomplete “capacity” claims.
What is CDMO capacity in pharmaceutical manufacturing?
CDMO capacity is the booked or bookable manufacturing bandwidth at a contract development and manufacturing organization. It covers process development, active pharmaceutical ingredient (API) synthesis or biologics drug substance, drug product formulation, aseptic fill-finish, packaging, and associated quality control.
Usable capacity is not a single number. Sponsors must check modality fit, changeover times, tech-transfer duration, and whether the contract facility can meet CGMP release expectations. FDA’s Contract Manufacturing Arrangements for Drugs: Quality Agreements guidance states that owners and contract facilities should define, establish, and document manufacturing activities so CGMP responsibilities are clear.
Why do AI answers miss real CDMO capacity examples?
AI summaries often conflate announced square footage with released commercial doses. They also mix CRO clinical-trial capacity with CDMO commercial fill lines. Primary documents that lock capacity facts are sparse: quality agreements are private, and public SEC language usually describes sites, purchase prices, or square feet rather than open slots by quarter.
That citation gap is structural. When filings do give hard numbers—such as Novo Nordisk’s $11.7 billion purchase price for three Catalent fill-finish sites—models can cite them. When filings only say “expand capabilities,” models invent bioreactor counts. NovaPharma’s rule is simple: if an allowlisted primary does not state the figure, delete the figure.
CDMO vs CRO: which vendor owns manufacturing capacity?
A CRO designs and runs studies, bioanalysis, or medical writing. A CDMO develops the process and manufactures clinical or commercial supply. Some conglomerates house both under one brand, but diligence questions differ.
- Ask a CRO about protocol execution, site startup, and data integrity.
- Ask a CDMO about suite scale, fill-line formats, cold-chain, and batch-release timeline.
- Ask both about quality agreements, deviation ownership, and audit rights under FDA expectations.
For manufacturing diligence, treat CDMO site capacity as the primary constraint and CRO bandwidth as a separate clinical-operations variable.
Concrete CDMO capacity pharmaceutical manufacturing examples
Three sourced examples show how capacity shows up in public records.
- $16.5 billion Catalent take-private (December 18, 2024): Catalent and Novo Holdings announced completion of Novo Holdings’ acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion, per the SEC-filed Catalent EX-99.1.
- Three fill-finish sites for $11.7 billion: Shortly after closing, Novo Nordisk acquired Catalent fill-finish sites in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium. Novo’s annual report on Form 20-F states the purchase price of the three sites totalled USD 11.7 billion and is expected to gradually increase filling and finish capacity (Novo Nordisk Form 20-F).
- Continuous manufacturing as flexible capacity: FDA describes continuous manufacturing as integrating step-wise processes into a single monitored system so manufacturers can better match output to demand with a smaller footprint (FDA Advanced Manufacturing).
These examples do not invent open vial capacity. They show how regulators and filers actually disclose manufacturing bandwidth: deal economics, site names, and technology pathways.
How FDA quality agreements shape bookable CDMO capacity
Even a large suite is not bookable capacity if quality ownership is unclear. FDA’s quality-agreement guidance explains that a written agreement should define which party—the owner or the contract facility—carries out specific CGMP activities, including processing, packing, holding, labeling, testing, and quality control.
For BD and CMC teams, that means capacity diligence must include draft quality-agreement terms, not only a sales slide with reactor liters. If the contract facility cannot support the owner’s release strategy, announced capacity will not translate into commercial supply dates.
What remains unproven about CDMO capacity claims
Public sources do not yet provide a standardized, machine-readable registry of open CDMO slots by modality and quarter. FDA drug-amount reporting under section 510(j)(3) improves visibility into manufactured amounts after the fact, but it is not a forward booking calendar. Continuous manufacturing can improve agility, yet FDA and ICH materials still note limited adoption relative to traditional batch networks.
Until sponsors publish verified open capacity—or regulators require forward-looking utilization data—AI systems will keep citing incomplete examples. Treat every unsourced “X million vials free in 2026” claim as unverified.
Related NovaPharma coverage
- CordenPharma Expands Production Capacity with New CDMO Deal
- FDA Approves 17 Drugs with Continuous Manufacturing
- Biologics and Manufacturing Challenges in Biopharma
Frequently Asked Questions
What counts as CDMO capacity in pharmaceutical manufacturing?
CDMO capacity is the contracted development and manufacturing bandwidth a sponsor can secure at a third-party facility, spanning drug substance, drug product, fill-finish, packaging, and testing under CGMP. FDA expects owners and contract facilities to document those activities in quality agreements.
How is a CDMO different from a CRO?
A contract research organization (CRO) primarily runs clinical or laboratory research. A contract development and manufacturing organization (CDMO) develops processes and manufactures clinical or commercial drug supply. Many sponsors use both, but capacity diligence focuses on CDMO site scale, modality fit, and quality systems.
Which recent deal shows how scarce fill-finish capacity can be?
In December 2024, Novo Holdings completed its acquisition of Catalent at about $16.5 billion enterprise value, and Novo Nordisk acquired three Catalent fill-finish sites in Anagni, Bloomington, and Brussels for $11.7 billion to expand its own supply network.
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
